Skip to main content
Erschienen in: Neurological Sciences 1/2010

01.02.2010 | Original Article

The FRAGAMP study: environmental and genetic factors in Parkinson’s disease, methods and clinical features

verfasst von: Alessandra Nicoletti, Pierfrancesco Pugliese, Giuseppe Nicoletti, Gennarina Arabia, Grazia Annesi, Michele De Mari, Paolo Lamberti, Simone Gallerini, Roberto Marconi, Antonio Epifanio, Letterio Morgante, Autilia Cozzolino, Paolo Barone, Giuseppina Torchia, Aldo Quattrone, Mario Zappia

Erschienen in: Neurological Sciences | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The Fattori di Rischio Ambientali e Genetici Associati alla Malattia di Parkinson (FRAGAMP) study is a multicenter case–control study carried out to evaluate the possible role of environmental and genetic factors in Parkinson’s disease (PD). Cases and controls were enrolled from five Movement Disorder centers in Central-Southern Italy. PD was diagnosed according to Gelb’s criteria while the control groups consisted of the spouses of the enrolled patients or of healthy controls matched by age and area of residence. Cases and controls underwent a standardised questionnaire and a blood sample was taken for molecular analyses. At the end of the study 585 cases and 481 control subjects (287 spouse-controls and 194 generic-controls) were enrolled. Patients had a Hoehn–Yahr score of 2.3 ± 0.8; 85% of them took levodopa and 47% had motor complications. The FRAGAMP study represents one of the largest case–control studies carried out in Europe to investigate the possible role of environmental and genetic factors in PD.
Literatur
1.
Zurück zum Zitat de Lau LML, Breteler MMB (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535CrossRefPubMed de Lau LML, Breteler MMB (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535CrossRefPubMed
2.
Zurück zum Zitat Tan EK, Khajavi M, Thornby JI et al (2000) Variability and validity of polymorphism association studies in Parkinson’s disease. Neurology 55:533–538PubMed Tan EK, Khajavi M, Thornby JI et al (2000) Variability and validity of polymorphism association studies in Parkinson’s disease. Neurology 55:533–538PubMed
3.
Zurück zum Zitat Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980CrossRefPubMed Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980CrossRefPubMed
4.
Zurück zum Zitat Pals P, Van Everbroeck B, Grubben B et al (2003) Case-control study of environmental risk factors for Parkinson’s disease in Belgium. Eur J Epidemiol 18:1133–1142CrossRefPubMed Pals P, Van Everbroeck B, Grubben B et al (2003) Case-control study of environmental risk factors for Parkinson’s disease in Belgium. Eur J Epidemiol 18:1133–1142CrossRefPubMed
5.
Zurück zum Zitat Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39CrossRefPubMed Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39CrossRefPubMed
6.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed
7.
8.
Zurück zum Zitat Magni E, Binetti G, Padovani A et al (1996) The Mini-Mental State Examination in Alzheimer’s disease and multi-infarct dementia. Int Psychogeriatr 8:127–134CrossRefPubMed Magni E, Binetti G, Padovani A et al (1996) The Mini-Mental State Examination in Alzheimer’s disease and multi-infarct dementia. Int Psychogeriatr 8:127–134CrossRefPubMed
9.
Zurück zum Zitat Schrag A, Barone P, Brown RG et al (2007) Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 22:1077–1092CrossRefPubMed Schrag A, Barone P, Brown RG et al (2007) Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 22:1077–1092CrossRefPubMed
10.
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442PubMed Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442PubMed
11.
Zurück zum Zitat Fahn S, Elton RL, the members of the UPDRS development committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB (eds) Recent developments in Parkinson’s disease. MacMillan, London, pp 153–163 Fahn S, Elton RL, the members of the UPDRS development committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB (eds) Recent developments in Parkinson’s disease. MacMillan, London, pp 153–163
12.
Zurück zum Zitat Munetz MR, Benjamin S (1988) How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 39:1172–1177PubMed Munetz MR, Benjamin S (1988) How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 39:1172–1177PubMed
13.
Zurück zum Zitat Andreasen NC (1984) Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City Andreasen NC (1984) Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City
14.
Zurück zum Zitat Stata corp (1995) STATA statistical software: release 6.0. STATA corporation, College Station Stata corp (1995) STATA statistical software: release 6.0. STATA corporation, College Station
15.
Zurück zum Zitat Bornebroek M, Breteler M (2003) Studying risk factors for Parkinson’s disease. Eur J Epidemiol 18:1113–1114CrossRefPubMed Bornebroek M, Breteler M (2003) Studying risk factors for Parkinson’s disease. Eur J Epidemiol 18:1113–1114CrossRefPubMed
16.
Zurück zum Zitat Cardon LR, Bell JI (2001) Association study designs for complex diseases. Nat Rev Genet 2:91–99CrossRefPubMed Cardon LR, Bell JI (2001) Association study designs for complex diseases. Nat Rev Genet 2:91–99CrossRefPubMed
17.
Zurück zum Zitat Frigerio R, Elbaz A, Sanft KR et al (2005) Education and occupations preceding Parkinson disease: a population-based case–control study. Neurology 65:1575–1583CrossRefPubMed Frigerio R, Elbaz A, Sanft KR et al (2005) Education and occupations preceding Parkinson disease: a population-based case–control study. Neurology 65:1575–1583CrossRefPubMed
18.
Zurück zum Zitat Firestone JA, Smith-Weller T, Franklin G et al (2005) Pesticides and risk of Parkinson disease: a population-based case–control study. Arch Neurol 62:91–95CrossRefPubMed Firestone JA, Smith-Weller T, Franklin G et al (2005) Pesticides and risk of Parkinson disease: a population-based case–control study. Arch Neurol 62:91–95CrossRefPubMed
19.
Zurück zum Zitat Miyawaki E, Lyons K, Pahwa R et al (1997) Motor complications of chronic levodopa therapy in Parkinson’s disease. Clin Neuropharmacol 20:523–530CrossRefPubMed Miyawaki E, Lyons K, Pahwa R et al (1997) Motor complications of chronic levodopa therapy in Parkinson’s disease. Clin Neuropharmacol 20:523–530CrossRefPubMed
20.
Zurück zum Zitat Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629CrossRefPubMed Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629CrossRefPubMed
21.
Zurück zum Zitat Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707CrossRefPubMed Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707CrossRefPubMed
22.
Zurück zum Zitat Schrag A, Ben Shlomo Y, Quinn N (2002) How common are complications of Parkinson’s disease? J Neurol 249:419–423CrossRefPubMed Schrag A, Ben Shlomo Y, Quinn N (2002) How common are complications of Parkinson’s disease? J Neurol 249:419–423CrossRefPubMed
23.
Zurück zum Zitat Gordis L (ed) (1996) Epidemiology. W.B. Saunders Company, Philadelphia Gordis L (ed) (1996) Epidemiology. W.B. Saunders Company, Philadelphia
Metadaten
Titel
The FRAGAMP study: environmental and genetic factors in Parkinson’s disease, methods and clinical features
verfasst von
Alessandra Nicoletti
Pierfrancesco Pugliese
Giuseppe Nicoletti
Gennarina Arabia
Grazia Annesi
Michele De Mari
Paolo Lamberti
Simone Gallerini
Roberto Marconi
Antonio Epifanio
Letterio Morgante
Autilia Cozzolino
Paolo Barone
Giuseppina Torchia
Aldo Quattrone
Mario Zappia
Publikationsdatum
01.02.2010
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 1/2010
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-009-0182-z

Weitere Artikel der Ausgabe 1/2010

Neurological Sciences 1/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.